Biopharmaceutical firm LENZ Therapeutics, developing vision therapy products, receives a consensus "Buy" rating from six analysts.
LENZ Therapeutics, a biopharmaceutical firm specializing in vision therapy, received a consensus "Buy" rating from six analysts, including "Overweight" from Piper Sandler and "Buy" from HC Wainwright, with average 12-month price targets at $35.00. LENZ's products LNZ100 and LNZ101 are in Phase III clinical trials for presbyopia treatment. Institutional investors hold 54.32% of the company's shares.
August 19, 2024
4 Articles